Related Experiment Video
Updated: Sep 20, 2025
Analyzing the Permeability of the Blood-Brain Barrier by Microbial Traversal through Microvascular Endothelial Cells
Published on: February 14, 2020
Impact of medium cut-off membranes on S100A12 and soluble receptor for advanced glycation end products
Berfu Korucu1, Hasan Yeter1, Sevim Gonen2
1Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.
Insights
Medium cut-off (MCO) dialyzers significantly reduced S100A12 levels in hemodialysis patients. This suggests MCO dialyzers may improve cardiovascular outcomes by optimizing S100A12 and sRAGE profiles.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Biomarkers
Background:
- Atherosclerosis and cardiovascular outcomes in hemodialysis (HD) patients are linked to S100A12 and soluble receptor for advanced glycation end products (sRAGE).
- The impact of different dialyzer types on these biomarkers is not fully understood.
Purpose of the Study:
- To investigate the effect of medium cut-off (MCO) dialyzers on S100A12 and sRAGE levels in HD patients compared to low-flux and high-flux dialyzers.
- To assess the S100A12/sRAGE ratio changes with different dialyzer types.
Main Methods:
- A single-site, prospective, observational study involving age and sex-matched HD groups (low-flux, high-flux, MCO).
- Blood samples were collected at baseline and after six months of follow-up.
- Levels of S100A12 and sRAGE were measured and analyzed.
Main Results:
- S100A12 levels remained constant in low-flux and high-flux groups but significantly decreased in the MCO group after six months.
- sRAGE levels remained constant across all groups.
- The S100A12/sRAGE ratio significantly decreased in the MCO group, while it remained constant in the other groups.
Conclusions:
- Prolonged use of MCO dialyzers is associated with improved S100A12 and sRAGE profiles in HD patients.
- Further long-term studies with larger cohorts are necessary to confirm the impact of MCO dialyzers on cardiovascular outcomes.
Introduction:
Of the most remarkable molecules associated with atherosclerosis and the cardiovascular outcome are S100A12 (10,379.5 Da) and soluble receptor for advanced glycation end products (sRAGE-42,803 Da) in the hemodialysis (HD) population. We designed a study investigating the effects of the medium cut-off (MCO) dialyzers focusing on S100A12 and sRAGE in HD patients compared with low-flux and high-flux dialyzers.
Methods:
This single-site, prospective, observational study comprises age and sex-matched HD groups (low-flux, high-flux, and MCO). Blood samples were drawn at baseline (predialysis and postdialysis) and the sixth month (predialysis).
Results:
Groups had similar demographic features and laboratory parameters. Baseline S100A12 levels of the groups were similar [34.3 (±66.5), 30.9 (±42.7), and 40.6 (±29.6); p = 0.13]. Compared to their baseline, the sixth-month S100A12 levels were constant in low-flux and high-flux group and significantly lower in MCO group (p = 0.16, p = 0.33, and p = 0.004). Baseline sRAGE levels of the groups were similar at baseline [2.8 (±0.8), 2.7 (±0.6), and 2.6 (±0.7); p = 0.65], and the sixth-month [2.9 (±0.5), 2.4 (±0.7), and 2.4 (±0.8); p = 0.24]. sRAGE levels remained constant in all groups [p = 0.84, p = 0.13, and p = 0.39]. S100A12/sRAGE ratio at baseline and sixth month was constant in low-flux [22.3 (±63.7) and 18.1 (±24.8); p = 0.17] and high-flux groups [11.9 (±15.3) and 13.1 (±5.8); p = 0.26], the ratio decreased significantly in MCO group [16.5 (±11.6) to 7.8 (±5.5); p = 0.03].
Conclusion:
Our study suggests that prolonged use of MCO dialyzers is associated with better S100A12 and sRAGE levels. Long-term studies with larger samples are needed to understand the effects of a better S100A12-sRAGE profile provided by MCO dialyzers on HD patients' cardiovascular outcomes.
